Table 2.
The efficacy of small molecule antiangiogenic drugs in previously treated thymic carcinomas
| Total (n = 17) | Apatinib (n = 13) | Anlotinib (n = 4) | P | |
|---|---|---|---|---|
| Partial response | 4 (23.5) | 4 (30.8) | 0 (0.0) | |
| Stable response | 11 (64.7) | 7 (53.8) | 4 (100.0) | |
| Progressive disease | 2 (11.8) | 2 (15.4) | 0 (0.0) | |
| Overall response rate, % | 23.5 | 30.8 | 0.0 | 0.519* |
| mPFS(95%CI), mo | 7.9 (6.5–9.3) | 7.0 (5.0–9.0) | 8.0 (2.7–13.3) | 1.000** |
| mOS(95%CI), mo | 47.0 (35.4–58.6) | 47.0 (43.7–50.2) | 0.076*** |
*p value calculated by Fisher’s exact test
**p value calculated by Wilcoxon rank sum test
***p value calculated by t test